Table 1 Summary of studies included in the rapid review

Ades et al. (2000) [19]

Cross-sectional

April 1997 - June 1998

North Thames, England

Anonymous testing

n/a

126,009

241 (0.19)

n/a

n/a

17

Balogun et al. (2000) [20]

Cross-sectional

January - December 1996

Greater London

and the Northern and Yorkshire

region, England

Anonymous testing

n/a

London − 25,940

Northern and Yorkshire − 6,675

Total − 32,615

London − 86 (0.33)

Northern and Yorkshire − 37 (0.22)

Total − 123 (0.37)

London − 55 (0.21)

Northern and Yorkshire − 16 (0.24)

Total – 71 (0.22)

n/a

17

Carey et al. (2018) [21]

Cross-sectional

August - October 2017

South-East London

Universal opt-out testing

1,012/1,038 (97)

1,012

10 (0.99)

9 (0.89)

Not reported

-

Cortina-Borja et al. (2016) [22]

Cross-sectional

April - June 2012

North Thames, England

Anonymous testing

n/a

31,437

30 (0.10)

n/a

n/a

17

Dannhorn et al. (2015) [23]

Cross-sectional

Unknown

Barking, Havering and Redbridge, London

Anonymous testing

n/a

1000

4 (0.4%)

n/a

n/a

-

Goldberg et al., (2001) [24]

Cross-sectional

January - December 1997

Dundee, Scotland

Anonymous testing

n/a

3,548

23 (0.65)

n/a

n/a

16

Hutchinson et al. (2004) [25]

Cross-sectional

mid March - mid October 2000

Scotland

Anonymous testing

n/a

30,259

88 (0.29)

n/a

n/a

17

Orkin et al. (2016) [26]

Cross-sectional

January - December 2013

London, England

Anonymous testing

n/a

1,000

5 (0.5)

1 (0.1)

n/a

13

Selvapatt et al. (2015) [27]

Cross-sectional

November 2003 - February 2013

London, England

Universal opt-out testing

Not reported

35,355

136 (0.38)

60 (0.17)

£5,469 per newly diagnosed individual

Treatment with DAAs - £9,139 per QALY

18

Ward et al. (2000) [28]

Cross-sectional

November 1997 - April 1999

London, England

Universal opt-out testing.

4,729/4,825 (98)

4,729

38 (0.80%)

27 (0.57)

Not reported

18